Cardinal Health (NYSE:CAH) has been selected as a distributor for Telix Pharmaceuticals' Gozellix®, an important development ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today provides an update on its commercial and ...

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

Telix Pharmaceuticals is leveraging its success with Illuccix to build a diversified theranostic platform, driving long-term value through ...

We are pleased to be building upon our successful relationship to bring the accuracy and clinical utility of gallium-based imaging to even more patients across the country with Gozellix®.” ...

To support the rollout, Cardinal Health has deployed Telix's ARTMS QUANTM Irradiation System® (QIS®) cyclotron technology, enabling standardized, high-efficiency and cost-effective production of ...